EMVision Medical Devices (EMV) Q3 2026 TU earnings summary

Executive summary

• Advanced pivotal trial for FDA De Novo clearance with eight hospitals actively recruiting and no device-related adverse events reported.

• International clinical awareness increased, with technology featured at major conferences and academic publications in progress.

• Multiple pre-hospital feasibility and usability studies for the First Responder device are nearing completion, including aeromedical and mobile stroke unit environments.

• Grant-funded emu™ M Regional Benefits Study progressing, with preparations underway for launch in 2H CY2026 and milestone payments received.

Financial highlights

• Cash reserves of $18.4 million as of 31 March 2026, up from $17.5 million in the previous quarter.

• Received $3.8 million R&D tax refund for FY25 (up from $2.1 million in FY24) and $0.4 million CRC-P grant milestone payment.

• Net operating cash inflow of $0.931 million for the quarter, with R&D expenditure at $1.083 million, staff costs at $1.836 million, and corporate administration costs at $0.504 million.

• Additional non-dilutive funding of $6.6 million available from current grant programs.

Outlook and guidance

• Pivotal trial recruitment and data collection ongoing, with final analysis to follow completion and unblinding.

• Reporting expected this quarter for multiple pre-hospital studies, supporting commercialisation milestones.

• Regional Benefits Study to launch in 2H CY2026, with further grant funding milestones anticipated.